161 related articles for article (PubMed ID: 28549419)
21. DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma.
Hauer K; Calzada-Wack J; Steiger K; Grunewald TG; Baumhoer D; Plehm S; Buch T; Prazeres da Costa O; Esposito I; Burdach S; Richter GH
Cancer Res; 2013 Jan; 73(2):967-77. PubMed ID: 23204234
[TBL] [Abstract][Full Text] [Related]
22. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of the oncogenic helix-loop-helix protein Id2 in Ewing sarcoma.
Park HR; Jung WW; Kim HS; Santini-Araujo E; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Tumori; 2006; 92(3):236-40. PubMed ID: 16869242
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis.
Li YJ; Dai YL; Zhang WB; Li SJ; Tu CQ
Clin Exp Med; 2017 Feb; 17(1):59-69. PubMed ID: 26678086
[TBL] [Abstract][Full Text] [Related]
25. CXCL16 and CXCR6 in Ewing sarcoma family tumor.
Na KY; Kim HS; Jung WW; Sung JY; Kalil RK; Kim YW; Park YK
Hum Pathol; 2014 Apr; 45(4):753-60. PubMed ID: 24507753
[TBL] [Abstract][Full Text] [Related]
26. ProGRP is a possible tumor marker for patients with Ewing sarcoma.
Yamaguchi K; Katagiri H; Takahashi M; Ishida Y; Ono A; Takahashi T; Ohshima K; Mochizuki T; Urakami K; Muramatsu K; Kameya T; Ito I; Nakajima T
Biomed Res; 2015; 36(4):273-7. PubMed ID: 26299486
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
28. Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells.
Kimura T; Wang L; Tabu K; Tsuda M; Tanino M; Maekawa A; Nishihara H; Hiraga H; Taga T; Oda Y; Tanaka S
Oncogene; 2016 Jul; 35(30):3932-43. PubMed ID: 26640147
[TBL] [Abstract][Full Text] [Related]
29. Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis.
Mancarella C; Caldoni G; Ribolsi I; Parra A; Manara MC; Mercurio AM; Morrione A; Scotlandi K
Front Oncol; 2020; 10():994. PubMed ID: 32719743
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens.
Fernandez-Pol S; van de Rijn M; Natkunam Y; Charville GW
Virchows Arch; 2018 Dec; 473(6):765-769. PubMed ID: 30014288
[TBL] [Abstract][Full Text] [Related]
31. Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.
Tilan JU; Krailo M; Barkauskas DA; Galli S; Mtaweh H; Long J; Wang H; Hawkins K; Lu C; Jeha D; Izycka-Swieszewska E; Lawlor ER; Toretsky JA; Kitlinska JB
Cancer; 2015 Mar; 121(5):697-707. PubMed ID: 25387699
[TBL] [Abstract][Full Text] [Related]
32. Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.
Kaemmerer D; Reimann C; Specht E; Wirtz RM; Sayeg M; Baum RP; Schulz S; Lupp A
Oncotarget; 2015 Feb; 6(5):3346-58. PubMed ID: 25671300
[TBL] [Abstract][Full Text] [Related]
33. IL6 secreted by Ewing sarcoma tumor microenvironment confers anti-apoptotic and cell-disseminating paracrine responses in Ewing sarcoma cells.
Lissat A; Joerschke M; Shinde DA; Braunschweig T; Meier A; Makowska A; Bortnick R; Henneke P; Herget G; Gorr TA; Kontny U
BMC Cancer; 2015 Jul; 15():552. PubMed ID: 26215971
[TBL] [Abstract][Full Text] [Related]
34. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow.
Dubois SG; Epling CL; Teague J; Matthay KK; Sinclair E
Pediatr Blood Cancer; 2010 Jan; 54(1):13-8. PubMed ID: 19711435
[TBL] [Abstract][Full Text] [Related]
36. Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma.
Bosma SE; van Driel PB; Hogendoorn PC; Dijkstra PS; Sier CF
J Surg Oncol; 2018 Nov; 118(6):906-914. PubMed ID: 30212597
[TBL] [Abstract][Full Text] [Related]
37. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
[TBL] [Abstract][Full Text] [Related]
38. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
39. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.
Moore C; Parrish JK; Jedlicka P
PLoS One; 2017; 12(5):e0178028. PubMed ID: 28542597
[TBL] [Abstract][Full Text] [Related]
40. High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.
Hong SH; Tilan JU; Galli S; Izycka-Swieszewska E; Polk T; Horton M; Mahajan A; Christian D; Jenkins S; Acree R; Connors K; Ledo P; Lu C; Lee YC; Rodriguez O; Toretsky JA; Albanese C; Kitlinska J
Oncotarget; 2015 Mar; 6(9):7151-65. PubMed ID: 25714031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
